Morgan Stanley
PTPI

Morgan Stanley’s Petros Pharmaceuticals PTPI Stock Holding History

Morgan Stanley’s Portfolio PTPI Stock Details PTPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28
Closed -$48 – 8236
2025
Q1 		$48 Buy
28
+27
+2,700% +$138 ﹤0.01% 7733
2024
Q4 		$8 Hold
1
– – ﹤0.01% 7917
2024
Q3 		$7 Hold
1
– – ﹤0.01% 7879
2024
Q2 		$9 Sell
1
-19
-95% -$305 ﹤0.01% 7787
2024
Q1 		$753 Buy
20
+18
+900% +$634 ﹤0.01% 7203
2023
Q4 		$54 Buy
2
+1
+100% +$36 ﹤0.01% 7646
2023
Q3 		$32 Hold
1
– – ﹤0.01% 7508
2023
Q2 		$39 Hold
1
– – ﹤0.01% 7551
2023
Q1 		$24 Hold
1
– – ﹤0.01% 7633
2022
Q4 		$40 Hold
1
– – ﹤0.01% 7743
2022
Q3 		$0 Hold
1
– – ﹤0.01% 7835
2022
Q2 		$0 Sell
1
-14
-93% -$3.51K ﹤0.01% 7932
2022
Q1 		$6K Hold
15
– – ﹤0.01% 7545
2021
Q4 		$13K Buy
15
+14
+1,400% +$8.2K ﹤0.01% 7386
2021
Q3 		$0 Hold
1
– – ﹤0.01% 8004
2021
Q2 		$1K Hold
1
– – ﹤0.01% 7625
2021
Q1 		$1K Hold
1
– – ﹤0.01% 7368
2020
Q4 		$1K Buy
+1
New +$941 ﹤0.01% 6960

Morgan Stanley's PTPI Position: Q2 2025 in Review

Morgan Stanley sold out of Petros Pharmaceuticals (PTPI) in Q2 2025, closing a stake of 28 shares — an estimated $48 sold.

Morgan Stanley first reported a position in PTPI in Q4 2020 and held it in 18 quarters. The position peaked at $13K in Q4 2021. 0 funds tracked by Wall St. Rank hold PTPI as of Q2 2025.

  • Morgan Stanley reported no remaining Petros Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Morgan Stanley sold 28 Petros Pharmaceuticals shares in Q2 2025, an estimated $48.
  • Morgan Stanley first reported a position in Petros Pharmaceuticals in Q4 2020 and held it in 18 quarters.
  • Morgan Stanley's Petros Pharmaceuticals position peaked at $13K in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q2 2025.

Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.